Search Results - "D. Sohal"

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children by Drilon, Alexander, Laetsch, Theodore W, Kummar, Shivaani, DuBois, Steven G, Lassen, Ulrik N, Demetri, George D, Nathenson, Michael, Doebele, Robert C, Farago, Anna F, Pappo, Alberto S, Turpin, Brian, Dowlati, Afshin, Brose, Marcia S, Mascarenhas, Leo, Federman, Noah, Berlin, Jordan, El-Deiry, Wafik S, Baik, Christina, Deeken, John, Boni, Valentina, Nagasubramanian, Ramamoorthy, Taylor, Matthew, Rudzinski, Erin R, Meric-Bernstam, Funda, Sohal, Davendra P.S, Ma, Patrick C, Raez, Luis E, Hechtman, Jaclyn F, Benayed, Ryma, Ladanyi, Marc, Tuch, Brian B, Ebata, Kevin, Cruickshank, Scott, Ku, Nora C, Cox, Michael C, Hawkins, Douglas S, Hong, David S, Hyman, David M

“…Fusions involving tropomyosin receptor genes are noted in cancers affecting children and adults. The TRK inhibitor larotrectinib induced a response in 75% of…”
Get full text

A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma by Sohal, D.P.S., Mykulowycz, K., Uehara, T., Teitelbaum, U.R., Damjanov, N., Giantonio, B.J., Carberry, M., Wissel, P., Jacobs-Small, M., O'Dwyer, P.J., Sepulveda, A., Sun, W.

“…Current data suggest that chemotherapy combinations may be superior to single agents in biliary tract cancer. The epidermal growth factor receptor (EGFR)…”
Get full text

Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS–MAPK pathway and TP53 as potential predictors of immunotherapy efficacy by Wang, J.Y., Xiu, J., Baca, Y., Arai, H., Battaglin, F., Kawanishi, N., Soni, S., Zhang, W., Millstein, J., Shields, A.F., Grothey, A., Weinberg, B.A., Marshall, J.L., Lou, E., Khushman, M., Sohal, D.P.S., Hall, M.J., Oberley, M., Spetzler, D., Shen, L., Korn, W.M., Lenz, H.J.

“…The impact of molecular alterations on programmed death-ligand 1 (PD-L1) combined positive score (CPS) is not well studied in gastroesophageal adenocarcinomas…”
Get full text

Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance by Barata, P.C., Koshkin, V.S., Funchain, P., Sohal, D., Pritchard, A., Klek, S., Adamowicz, T., Gopalakrishnan, D., Garcia, J., Rini, B., Grivas, P.

“…Advances in cancer genome sequencing have led to the development of various next-generation sequencing (NGS) platforms. There is paucity of data regarding…”
Get full text

The clinical impact of targeted next generation sequencing (tNGS) in the treatment of metastatic prostate cancer by Coelho Barata, P.M.C., Mendiratta, P., Sadaps, M., Klek, S., Ornstein, M., Gilligan, T., Grivas, P., Rini, B.I., Sohal, D., Garcia, J.A.

Get full text

Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational status by Faber, E.B., Baca, Y., Xiu, J., Walker, P., Manji, G., Gholami, S., Saeed, A., Prakash, A., Botta, G.P., Sohal, D., Lenz, H.J., Shields, A.F., Nabhan, C., El-Deiry, W., Seeber, A., Chiu, V., Hwang, J., Lou, E.

“…Background: The majority of pancreatic ductal adenocarcinomas (PDACs) are driven by mutant (mt) KRAS. How mt KRAS and co-driver mutations affect the immune…”
Get full text

Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors by Perez, B., Aljumaily, R., Marron, T.U., Shafique, M.R., Burris, H., Iams, W.T., Chmura, S.J., Luke, J.J., Edenfield, W., Sohal, D., Liao, X., Boesler, C., Machl, A., Seebeck, J., Becker, A., Guenther, B., Rodriguez-Gutierrez, A., Antonia, S.J.

“…We report results from a phase I, three-part, dose-escalation study of peposertib, a DNA-dependent protein kinase inhibitor, in combination with avelumab, an…”
Get full text

Gefitinib in definitive management of esophageal or gastroesophageal junction cancer: a retrospective analysis of two clinical trials by Sohal, D. P. S., Rice, T. W., Rybicki, L. A., Rodriguez, C. P., Videtic, G. M. M., Saxton, J. P., Murthy, S. C., Mason, D. P., Phillips, B. E., Tubbs, R. R., Plesec, T., McNamara, M. J., Ives, D. I., Bodmann, J. W., Adelstein, D. J.

“…Summary The role of epidermal growth factor receptor inhibition in resectable esophageal/gastroesophageal junction (E/GEJ) cancer is uncertain. Results from…”
Get full text

Gene Expression Signature Associated With Rectal Cancers With Poor Response To Chemoradiation by Gantt, G.A, Chen, Y, Sohal, D, DeJulius, K, Mace, A.G, Barnholtz-Sloan, J.S, Kalady, M.F

Get full text

Temporally Regulated and Tissue-Specific Gene Manipulations in the Adult and Embryonic Heart Using a Tamoxifen-Inducible Cre Protein by Sohal, Dawinder S, Nghiem, Mai, Crackower, Michael A, Witt, Sandra A, Kimball, Thomas R, Tymitz, Kevin M, Penninger, Josef M, Molkentin, Jeffery D

“…ABSTRACT—The advent of conditional and tissue-specific recombination systems in gene-targeted or transgenic mice has permitted an assessment of single gene…”
Get full text

Patterns of Failure after Trimodality Therapy for Pancreatic and Duodenal Cancers by Miller, S.M, Ali, A.N, Mick, R, Moghanaki, D, Furth, E.E, Sohal, D, Giantonio, B.J, Plastaras, J.P

Get full text

The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis by Mulder, Frits I, Candeloro, Matteo, Kamphuisen, Pieter W, Di Nisio, Marcello, Bossuyt, Patrick M, Guman, Noori, Smit, Kirsten, Büller, Harry R, van Es, Nick

“…We aimed to evaluate the performance of the Khorana score in predicting venous thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were…”
Get full text

1139P Carcinoma of unknown primary (CUP): The role of tumor genomic profiling by Park, C., Georlette, D., Korn, W.M., Xiu, J., Babiker, H., Coelho Barata, P.M., Sohal, D.

Get full text

Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy by Sohal, Davendra P S, Walsh, R Matthew, Ramanathan, Ramesh K, Khorana, Alok A

“…Pancreatic adenocarcinoma, even when resectable, remains highly lethal. Although surgical outcomes have improved considerably, median overall survival after…”
Get full text

Predictors of nonresection following neoadjuvant therapy for resectable PDAC: Analysis of SWOG S1505 by Cloyd, J.M., Colby, S., Guthrie, K.A., Lowy, A.M., Chiorean, G., Philip, P., Sohal, D., Ahmad, S.

Get full text

Feasibility Trial of IMPT to Reduce Toxicity in Anal Cancer Patients by Nelson, B., Meier, T., Zhang, Y., Wang, K., Mascia, A.E., Paquette, I., Thompson, E., Rafferty, J., Olowokure, O., Sohal, D., Kharofa, J.R.

Get full text

National assessment of margin positive pancreatectomy in pancreatic adenocarcinoma by Turner, K., Lim, S.A., Delman, A., Smith, M., Sohal, D., Olowokure, O., Choe, K., Kharofa, J., Ahmad, S., Wilson, G., Patel, S.

Get full text

1229P A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers by Ko, A.H., Noel, M., Chao, J., Sohal, D., Crow, M., Oberstein, P.E., Scott, A., McRee, A., Rocha Lima, C., Fong, L., Keenan, B., Filbert, E., Hsu, F.J., Shankaran, V.

Get full text

480P Gene expression of NANOG and NANOGP8 in colorectal cancer by Arai, H., Baca, Y., Xiu, J., Battaglin, F., Hwang, J., Marshall, J.L., Goldberg, R.M., Weinberg, B.A., Sohal, D., Lou, E., Hall, M.J., Wang, J., Kawanishi, N., Jayachandran, P., Soni, S., Zhang, W., Magee, D., Korn, W.M., Lenz, H.J.

Get full text

1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer by Cabanillas, M.E., Drilon, A., Farago, A.F., Brose, M.S., McDermott, R., Sohal, D., Oh, D-Y., Almubarak, M., Bauman, J., Chu, E., Kummar, S., Leyvraz, S., Park, K., Reeves, J.A., Dima, L., Maeda, P., Rodrigues, L., Brega, N., Hong, D.S., Waguespack, S.G.

Get full text